ESTRO meets Asia 2024 - Abstract Book

S100

Interdisciplinary – CNS

ESTRO meets Asia 2024

A total of 107 patients were included and the median iPFS in these patients treated with SIB-WBRT was 13.4 (95% CI: 4.2-22.6) months, with 66.3% (95% CI: 56.0%-77.0%) and 48.5% (95% CI: 36.0%-61.0%) iPFS at 6- and 12-months. The median local control was 37.6 (95% CI: 28.3-46.8) months, with local control rates of 83.9% (95% CI: 80.0%- 88.0%) and 72.6% (95% CI: 67.0%-78.0%) at 6- and 12-months. The median time to appearance of new intracranial foci was 17.4 (95% CI: 17.1-20.8) months, and the 6- and 12-month control rates were 72.6% (95% CI: 62.0%-83.0%) and 58.8% (95% CI: 46.0%-72.0%). The number of brain metastases in patients before treatment was significantly associated with iPFS (HR=0.4, 95% CI: 0.1-0.9, P=0.0430).

Conclusion:

The iPFS, local control, and intracranial new foci of patients with brain metastases after treatment with SIB-WBRT were acceptable. In addition, the number of brain metastases in patients before treatment may be associated with iPFS.

Keywords: radiotherapy,simultaneous integrated boost,cancer

References:

1. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN. 2023; 21: 12-20.

2. Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018; 36: 483-91.

3. Westover KD, Mendel JT, Dan T, Kumar K, Gao A, Pulipparacharuv S, et al. Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol. 2020; 22: 1831-9.

4. Rades D, Johannwerner L, Werner EM, Cremers F, Yu NY. The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases. Biology. 2023; 12.

5. Bostel T, Akbaba S, Wollschläger D, Mayer A, Nikolaidou E, Murnik M, et al. Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly. Frontiers in oncology. 2023; 13: 1063670. 6. Loesch D, Robert N, Jones S, Elkordy M, Ilegbodu D, Asmar L. Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study. Journal of oncology practice. 2006; 2: 268-73. 7. van Loon J, Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer. 2009; 45: 588-95.

8. Wu X, Xia Y, Hou Y, Li L, Wang L, Li R, et al. Analysis of the efficacy and prognostic factors of linear accelerator based hypofractionated stereotactic radiotherapy for brain metastasis of non-small-cell lung cancer. 2020.

9. Pihlak R. Improving Outcomes in Patients with a Diagnosis of Pancreatic Cancer: The University of Manchester (United Kingdom); 2021.